Delivery Order SPE2DB22D1106-SPE2DB24FEFT9
Award Date 3/19/24
Potential Completion Date 3/20/24
Potential Value $3.8K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $2,065.21 firm fixed price delivery order contract (SPE2DX15D3504|SPE2DX24F05K0) for the supply of ELIQUIS 5 MG TABLET 60S. This order is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to provide pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,900.08 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide ELIQUIS 2.5 MG TABLET 60S. This delivery order is part of an Indefinite Delivery Contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to deliver pharmaceutical products and medical supplies in support of military treatment programs and facilities...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $1,900.08 to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical company Amerisourcebergen Corporation. This order is for the supply of ELIQUIS 2.5 mg tablets and is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
- The U.S. Defense Logistics Agency (DLA) awarded a $3,800.16 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp for the supply of 4565253592 ELIQUIS 2.5 MG TABLET 60S. This order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and Amerisourcebergen, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a $1,599.60 firm fixed price delivery order contract to provide ELIQUIS 5 MG TABLET 60S. This order falls under a larger, single-award, indefinite delivery contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA. The IDC serves as the primary vehicle for Amerisourcebergen to deliver pharmaceutical products and...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a $1,900.08 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of 4565177698 ELIQUIS 2.5 MG TABLET 60S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of pharmaceutical and medical supplies to...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $33,787.43 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation. The contract is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a performance period through April 11, 2024. This delivery order is a part of a larger indefinite delivery contract (IDC) worth up to $999,999,999.00 that AmerisourceBergen Drug...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division, a for-profit pharmaceutical distributor. The $2,850.12 contract is for the supply of 4565243575 ELIQUIS 2.5 MG TABLET 60S. This order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for delivering a range of medical commodities to support military treatment...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of $1,900.08 worth of ELIQUIS 2.5 MG TABLET 60S. The contract, which does not have a set-aside designation, is for the period of February 1, 2024 through February 2, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA Troop...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of ELIQUIS 2.5 MG TABLET 60S. The $3,800.16 contract has a performance period through January 29, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor for this award, which is part of the company's larger indefinite...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB24FEFT9Delivery Order
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $3,800.16 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of 4564016271 ELIQUIS 2.5 MG TABLET 60S. This delivery order is a part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 awarded by DLA to AmerisourceBergen Drug Corp, which serves as the primary vehicle for the company to provide pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. The contract has an ultimate completion date of March 20, 2024 and does not include any set-aside designation.
Generated 6/18/24, 3:24 PM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 3/19/24 |